Been watching the oral nicotine category pretty closely lately, and there's something interesting happening that most people might be overlooking. Altria's really doubling down on this space, and the numbers are pretty compelling.

So here's what caught my attention. Nicotine pouches are basically becoming the core of Altria's smoke-free strategy now. In their latest earnings, they highlighted how the category grew 14% over six months, which is solid momentum. By Q4 2025, nicotine pouches made up nearly 57% of their entire oral category, up 10.4 share points year over year. That's a pretty decisive shift in how consumers are moving within oral tobacco.

What's really interesting is how Altria's handling the pricing dynamics here. The broader nicotine pouches market saw pricing decline roughly 12% year over year due to competitive pressure, right? But on! didn't follow that race to the bottom. They actually implemented a 3% price increase while maintaining market share. That takes discipline. For 2025, on! shipped over 177 million cans with an 8.2% retail share, up 0.1 share points. Not massive growth, but they're holding ground despite the pricing chaos.

The real catalyst coming is on! PLUS, which just got FDA approval. It's their premium wet pouch offering launching in the first half of 2026. Higher nicotine strengths, better mouthfeel. They're essentially trying to segment the market upward, which makes sense given how price-sensitive the overall category has become.

Now, context matters here. Philip Morris has been crushing it with smoke-free products, pulling in $16.9 billion in 2025 with IQOS and ZYN momentum. That's 41.5% of their total revenue. Then you've got Turning Point Brands absolutely exploding with their Modern Oral segment, up 627.6% year over year by Q3 2025. FRE and ALP brands are driving that surge. They're now guiding $125-130 million for full-year 2025 in that category alone.

So Altria's in a competitive position where they need to prove oral nicotine can be a real growth engine, not just a defensive play. The pricing strategy they're executing on nicotine pouches is actually pretty smart, especially when you consider how saturated some parts of the market have become. They're not trying to win on volume alone, they're protecting margins while the category matures.

Valuation-wise, MO is trading at 12.32X forward P/E, which is below the industry average of 16.2X. Consensus estimates for 2026 and 2027 EPS are $5.57 and $5.76 respectively. Stock's up 10.9% in the past month versus 5% for the broader industry. Could be worth keeping on the radar if you're looking at the smoke-free transition story, especially with on! PLUS coming to market.